Overexpression of prostate stem cell antigen (PSCA), a prostate-specific glycosyl phosphatidylinositol-anchored glycoprotein found in prostate cancer PC3 cells, was the binding site for the scAbPSCA-conjugated nanoparticles.20 Targeted PLGA nanoparticles demonstrated improved cellular uptake and cytotoxicity in PC3 prostate cancer cells exhibited an IC50 of 0.01403 μg mL−1 (24 h), 0.00579 μg mL−1 (48 h) and 0.00322 μg mL−1 (72 h).21 Herein, the scAbPSCA-conjugated nanoparticles showed a time-dependent cytotoxicity against prostate cancer PC3 cells. The gene discussed is PSCA; the disease is prostate carcinoma.